in patients with symptomatic oral lichen planus (OLP). The 0.50 mg cohort was treated over a four-week period, with Week 4 serving as the primary endpoint. Week 6 data reflect follow-up ...

These do not show any noticeable pathology apart from missing follicular orifices (Figure ... integument may give further evidence for lichen planus. If alopecia is the only symptom it is ...

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP). The ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

LP-310 is being developed as a non-steroidal, locally delivered treatment for oral lichen planus, a chronic inflammatory condition with no FDA-approved therapies.

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP).